A PYMNTS Company

US: Mylan seeks dismissal of Sanofi’s EpiPen antitrust suit

By  |  July 2, 2019

Mylan is urging a federal judge to reject rival drugmaker Sanofi’s claims the company engaged in a scheme to squelch competition to its EpiPen allergy treatment, which became the center of a political firestorm over price increases.

    Get the Full Story

    Complete the form to unlock this article and enjoy unlimited free access to all PYMNTS content — no additional logins required.

    yesSubscribe to our daily newsletter, PYMNTS Today.

    By completing this form, you agree to receive marketing communications from PYMNTS and to the sharing of your information with our sponsor, if applicable, in accordance with our Privacy Policy and Terms and Conditions.

    Mylan in a brief filed on Friday in federal court in Kansas City, Kansas, argued Sanofi lacked evidence to support claims it took actions to “crush” the competitive threat posed by Sanofi’s newer product, Auvi-Q.

    The suit filed  in Trenton, NJ, Sanofi said Mylan caused it to lose hundreds of millions of dollars in sales by erecting barriers to US consumers’ access to and use of a rival product, Auvi-Q.

    In particular, Sanofi said Mylan offered rebates to insurers, pharmaceutical benefit managers and state Medicaid agencies conditioned on Auvi-Q not being an epinephrine auto-injector device they would reimburse for use by consumers.

    Full Content: Reuters

    Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.